Related Experiment Video
Updated: Dec 13, 2025
Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography
Published on: January 27, 2023
Patent Ductus Arteriosus-Time for a Definitive Trial
Souvik Mitra1, Patrick J McNamara2
1Department of Pediatrics, Dalhousie University, G-2214, 5850/5980 University Avenue, Halifax, Nova Scotia B3K 6R8, Canada; Department of Community Health & Epidemiology, Dalhousie University, G-2214, 5850/5980 University Avenue, Halifax, Nova Scotia B3K 6R8, Canada. Electronic address: https://twitter.com/souvik_neo.
Treating patent ductus arteriosus (PDA) in preterm infants remains uncertain. Current evidence is limited by trial design flaws, impacting clinical outcome understanding and treatment decisions.
Area of Science:
- Neonatal Medicine
- Pediatric Cardiology
- Clinical Trials
Background:
- Over 70 randomized controlled trials (RCTs) exist for managing patent ductus arteriosus (PDA) in preterm infants.
- Clinical uncertainty persists regarding whether PDA treatment improves significant patient outcomes.
- Previous trials focused on pharmacologic closure but had design limitations (older infants, varied definitions, open-label).
Purpose of the Study:
- To evaluate the impact of current evidence on clinical decision-making for PDA management in preterm infants.
- To identify limitations in existing RCTs that hinder definitive conclusions on PDA treatment efficacy.
- To address the growing consideration of 'no treatment' as a viable option regardless of infant and PDA characteristics.
Main Methods:
- Systematic review of over 70 randomized controlled trials on PDA management in preterm infants.
- Analysis of trial designs, including participant age, PDA definitions, and treatment blinding.
- Assessment of the influence of trial methodologies on the interpretation of clinical outcomes.
Main Results:
- Existing RCTs on PDA management in preterm infants exhibit significant design flaws.
- Varied PDA definitions and open-label treatments in older trials complicate outcome interpretation.
- Methodological limitations may contribute to uncertainty about the benefits of PDA treatment.
Conclusions:
- Current evidence on PDA management in preterm infants is insufficient to guide clinical practice definitively.
- Limitations in past research hinder the ability to ascertain the clinical benefits of PDA treatment.
- Further well-designed trials are needed to clarify the optimal management strategy for PDA in this population.
